Gen

Belgian-based Ablynx has signed an exclusive collaboration agreement with Sanofi subsidiary Genzyme for a research project on multiple sclerosis (MS).

Under the deal, the firmsc will investigate Nanobodies against a target that plays a crucial role in MS. The project will specifically align with Genzyme’s early-stage MS research programmes involving neuroprotection and CNS repair.

Ablynx is involved in the development of Nanobodies, a therapeutic proteins based on single-domain antibody fragments that aggregate the advantages of conventional antibody drugs with some of the features of small-molecule drugs.

Ablynx CEO Dr Edwin Moses said: "As a leading biotech company, Genzyme is an ideal partner to demonstrate the potential value of Ablynx’s versatile Nanobody technology platform in MS.

"The formatting flexibility of Nanobodies makes them promising candidates for combining antibody-like selectivity and multi-specificity in a single molecule."

"The formatting flexibility of Nanobodies makes them promising candidates for combining antibody-like selectivity and multi-specificity in a single molecule."

The deal will allow Genzyme to carry out in-vitro and in-vivo research with Ablynx’s Nanobodies in MS-relevant models in return for an exclusivity fee.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genzyme will have the option to negotiate a licence agreement, upon completion of these studies.

Ablynx said that it already generated potent Nanobodies against the specific target of interest and confirmed their activity in pre-clinical models.

Genzyme neuroimmunology research vice-president Johanne Kaplan said: "We look forward to collaborating with Ablynx to evaluate the potential of Nanobodies against this CNS target, as this project supports our research that includes the exploration of novel therapeutic platforms to address unmet needs in multiple sclerosis."


Image: Entrance to Genzyme building at 500 Kendall Square in Cambridge, Massachusetts. Photo: courtesy of Tim Pierce.